- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03817333
The Mixed Phenotype of Asthma and COPD: the Overlap Syndrome
The Mixed Phenotype of Asthma and COPD: the Overlap Syndrome: A Comparison of Asthma Outcomes in Smoking vs Non-smoking Patients With an Incomplete Reversibility of Airway Obstruction (IRAO)
RATIONALE:
In asthmatic subjects, smoking can lead to several changes in disease characterictics. in smokers of more than 20 pack-years, chronic obstructive pulmonary disease (COPD) can be associated with asthma, also called asthma-COPD overlap syndrome (ACOS). Increasing data support the concept that ACOS is a clinical entity. However, this should be further studied in order to better target therapy.
AIM:
The objective of this study is to evaluate the comparative features of ACOS
METHODS:
This will be a descriptive study comparing the features of the ACOS with the features of asthmatic subjects with an incomplete reversibility of airway obstruction (IRAO).The study will be done over 1 or 2 visits (within a week interval), according to subjects' availability. The visit will include completion of different questionnaires (asthma control asthma quality of life, medical history, exacerbations, etc.), a thoracic examination, allergy skin-prick tests, spirometry and bronchodilator response, lung volumes and compliance measurements, exhaled nitric oxide measurement, blood sampling and a sputum induction.
Přehled studie
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
Quebec, Kanada, G1V 4G5
- Institut Universitaire de cardiologie et de pneumologie de Quebec
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
ALL SUBJECTS
- Subjects aged 45 years and older.
- Free of any other respiratory condition, except for asthma and/or COPD, which may interfere with the tests.
- Asthma that requires a baseline treatment with inhaled corticosteroids and/or additional asthma medication.
- Free of respiratory infection in the 4 weeks preceding the study.
- No changes in the asthma and COPD-related medications in the 4 weeks preceding the study.
- If female, not pregnant (or lactating).
- Able to adhere to study procedures.
- Able and willing to provide written informed consent to participate in the study, in accordance with international conference on harmonization (ICH) good clinical practice (GCP) requirements.
ACOS SUBJECTS
1. Smokers or ex-smokers of at least 20 pack-years. 2. With an IRAO (see definitions section). IRAO SUBJECTS
- Long-life non-smokers or ex-smokers defined as someone who smoked less than 5 pack-years and who completely stopped smoking for at least 12 months before inclusion in the study.
- With an IRAO.
Exclusion Criteria:
ALL SUBJECTS
- With COPD without a past diagnosis of asthma.
- Unstable respiratory or non-respiratory condition.
- Any active chronic inflammatory disease.
- Any evidence of malignancy (active and/or treated) within the previous 5 years.
- Any significant concomitant illness or injury that would interfere with the subject's participation in the study.
- Any history of bronchial thermoplasty. IRAO SUBJECTS
- Use of any nicotine containing product within 1 year prior to study entry or a smoking history of > 5 pack-years.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
|---|
|
ACOS smoking history >20 pack-years
Subjects with asthma-COPD overlap syndrome
|
|
IRAO smoking history <5 pack-years
Subjects with an incomplete reversibility of airway obstruction
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Total asthma control questionnaire (ACQ) score
Časové okno: Baseline
|
Measurement of asthma control using a 0-6 scale.
The questionnaire includes 6 questions.
Total score is the mean of the scores from all questions.
Total score ranges from 0 to 6.
A lower score is better.
|
Baseline
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Spirometry results
Časové okno: Baseline
|
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC
|
Baseline
|
|
Sputum eosinophil percentage
Časové okno: Baseline
|
Percentage of sputum eosinophils
|
Baseline
|
|
Concentration of Blood biomarkers
Časové okno: Baseline
|
alpha 1 antitrypsine, C-reactive protein (CRP), fibrinogen
|
Baseline
|
|
Asthma quality of life questionnaire (AQLQ) score
Časové okno: Baseline
|
Measurement of asthma quality of life using the Mini asthma quality of life questionnaire.
It is a 7-point scale questionnaire (where 1 is greatest impairment and 7 is least impairment) containing 15 uqestions divided into 4 domains : symptoms (5 items), activity limitation (4 items), emotional function (3 items), and exposure to environmental stimuli (3 items).
during the last 2 weeks.
The overall score is the mean of all the responses.
Each domain score is calculated from the mean of the items that relate to it.
|
Baseline
|
|
Number of patients with comorbidities
Časové okno: Baseline
|
gastro-oesophageal reflux disease (GERD), obstructive sleep apnea (OSA), anxiety, depression
|
Baseline
|
|
Number of asthma exacerbations in the previous year
Časové okno: Baseline
|
emergency room (ER) visits, hospitalizations, oral corticosteroids treatment, unscheduled medical visits
|
Baseline
|
|
Change from baseline total Asthma Control Questionnaire (ACQ) score at one-year follow-up
Časové okno: Baseline to one-year follow-up
|
Measurement of asthma control using a 0-6 scale.
The questionnaire includes 6 questions.
Total score is the mean of the scores from all questions.
Total score ranges from 0 to 6.
A lower score is better.
|
Baseline to one-year follow-up
|
|
Change from baseline number of exacerbations at one-year follow-up
Časové okno: Baseline to one-year follow-up
|
emergency room (ER) visits, hospitalizations, oral corticosteroids treatment, unscheduled medical visits
|
Baseline to one-year follow-up
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CÉR21047
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .